Charco Neurotech

Charco Neurotech is a Cambridge-based medtech company founded in 2019 that develops a non-invasive wearable medical device called the CUE1, designed to improve movement and quality of life for people with Parkinson’s disease. The device uses pulsed cueing and high-frequency focused vibrotactile stimulation to alleviate symptoms such as slowness, stiffness, rigidity, and freezing of gait. Charco primarily serves individuals with Parkinson’s and healthcare providers, aiming to offer a simple, effective therapeutic option that can be prescribed through health systems like the NHS and Medicaid. The company has demonstrated strong growth, raising over $10 million in funding, employing around 38 people across the UK, South Korea, and the US, and having sold over 3,000 devices with ongoing regulatory approvals underway[1][3][4].

Charco Neurotech was co-founded by Lucy Jung, who brought personal insight into patient needs after her own health challenges and research on Parkinson’s therapies. The idea emerged from university research and evolved through close collaboration with the Parkinson’s community and clinical experts. Early traction included pilot studies showing clinically significant improvements in movement and partnerships with institutions like Addenbrookes Hospital to integrate the device into patient care. The company’s participation in accelerator programs such as Medtech SuperConnector and Cambridge Judge Business School helped shape its strategic direction and growth[1][2][4][5].

Core Differentiators

• Product innovation: The CUE1 device uniquely combines pulsed cueing with high-frequency vibrotactile stimulation to target Parkinson’s motor symptoms non-invasively.
• User-centered design: Developed with continuous input from people with Parkinson’s, ensuring usability, comfort, and real-world efficacy.
• Clinical validation: Pilot users showed an average improvement of 7.8 points on the MDS-UPDRS scale, a clinically meaningful change.
• Multidisciplinary team: Combines expertise from design engineers, clinicians, and Parkinson’s specialists.
• Fast iteration and community engagement: Agile development informed by direct feedback from users and healthcare providers.
• Regulatory progress: Approved for sale on the NHS, with FDA approval targeted soon[1][2][3][4].

Role in the Broader Tech Landscape

Charco Neurotech rides the growing trend of digital and wearable health technologies aimed at managing chronic neurological conditions. The timing is favorable due to increasing Parkinson’s prevalence globally, rising demand for non-pharmaceutical therapies, and advances in wearable sensor and stimulation technologies. The company’s approach exemplifies a shift toward patient-centered, data-driven, and non-invasive interventions that can be integrated into healthcare systems. By improving symptom management and potentially reducing hospital stays, Charco contributes to evolving standards of care and supports the broader ecosystem of neurotechnology innovation[1][2][4].

Quick Take & Future Outlook

Looking ahead, Charco Neurotech is positioned to expand its market reach with regulatory approvals in the US and Europe, scale production, and enhance its digital ecosystem through the CUE app for symptom tracking and medication reminders. Trends such as personalized medicine, remote patient monitoring, and integration of AI in neurotherapeutics will likely shape its trajectory. As the company grows, it may influence broader adoption of wearable neurostimulation devices and inspire further innovation in managing Parkinson’s and other neurological disorders. Charco’s commitment to community collaboration and scientific rigor suggests it will remain a key player in improving quality of life for people with Parkinson’s[1][3][4].